检索结果 - Sanjeev Deva

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

    Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors 由 Jared Odegard, Ahmed A. Othman, Kai-Wen Lin, Adele Y. Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P. Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    A Randomized Hybrid‐Effectiveness Trial Comparing Pharmacogenomics (<scp>PGx</scp>) to Standard Care: The <scp>PGx</scp> Applied to Chronic Pain Treatment in Primary Care (<scp>PGx</scp>‐<scp>ACT</scp>) Trial

    A Randomized Hybrid‐Effectiveness Trial Comparing Pharmacogenomics (<scp>PGx</scp>) to Standard Care: The <scp>PGx</scp> Applied to Chronic Pain Treatment in Primary Care (<scp>PGx... 由 D. Max Smith, Robel Beyene, Paul Kolm, Thomas Young, Sara Zifa, Victoria Natividad, A. La Licata, Robert H. Podolsky, Troy Moore, R. Matthew Walsh, Sanjeev Deva, Alexander D. Walker, Michael B. Jacobs, Beth N. Peshkin, Sandra M. Swain

    出版 2025
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

    Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors 由 Jayesh Desai, Sanjeev Deva, Jong Seok Lee, Chia‐Chi Lin, Chia-Jui Yen, Yee Chao, Bhumsuk Keam, Michael B. Jameson, Ming-Mo Hou, Yoon‐Koo Kang, Ben Markman, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa G. Horvath, Michael Friedlander, Andrew G. Hill, Shahneen Sandhu, Paula Barlow, Chi-Yuan Wu, Yun Zhang, Liang Liang, John Wu, Virginia Paton, Michael Millward

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: